In contrast, researchers found no link between levels of the factor and relapses or disability levels.
“Blood tests for this nerve protein may be an effective way to monitor disease activity and how well the treatment is working,” said Varhaug.
Researchers underscored that the study performed MRI scans far more often than is customary in regular MS care. In future studies, they hope to follow patients for a longer period to see how the relevance of the factor plays out in the long term.
Neurofilament light chain, a component of nerve cells, is currently being explored in numerous MS studies and clinical trials. Until it has been properly evaluated, it is, however, not part of standard MS care.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?